[Etiological drug therapy for amyotrophic lateral sclerosis]

Area of Science:

• Neurology
• Neuroscience
• Pharmacology

Background:

• Significant advancements in understanding amyotrophic lateral sclerosis (ALS) etiopathogenesis have spurred investigations into novel therapeutic targets.
• Research has focused on modulating excitotoxicity, oxidative stress, apoptosis, growth factors, and inflammation in ALS.

Framework:

• Riluzole has demonstrated efficacy in reducing mortality in ALS patients by 35% at 18 months, suggesting a neuroprotective role.
• Despite promising targets, numerous other compounds investigated for ALS treatment have yielded disappointing results, with some even exacerbating the condition.

Implementation:

• Clinical trials have evaluated various compounds targeting key pathological pathways in ALS.
• The efficacy of Riluzole in improving survival outcomes in ALS patients has been established.

Implications:

• Negative outcomes from trials of other compounds highlight the complexity of ALS pathophysiology.
• These findings raise critical questions about the translatability of animal models to human ALS and potential drug-drug interactions with Riluzole.